| Literature DB >> 35805032 |
Verona E Bergshoeff1,2, Maschenka C A Balkenhol1,3, Annick Haesevoets4, Andrea Ruland4, Michelene N Chenault1,5, Rik C Nelissen1,6, Carine J Peutz4, Ruud Clarijs7, Jeroen A W M Van der Laak3, Robert P Takes8, Michiel W Van den Brekel9, Marie-Louise F Van Velthuysen10, Frans C S Ramaekers11, Bernd Kremer1, Ernst-Jan M Speel4.
Abstract
BACKGROUND: The definition of objective, clinically applicable evaluation criteria for FISH 1c/7c in laryngeal precursor lesions for the detection of chromosome instability (CI). Copy Number Variations (CNV) for chromosomes 1 and 7 reflect the general ploidy status of premalignant head and neck lesions and can therefore be used as a marker for CI.Entities:
Keywords: FISH; chromosome instability; dysplasia; head and neck cancer; larynx; premalignant
Year: 2022 PMID: 35805032 PMCID: PMC9265082 DOI: 10.3390/cancers14133260
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Evaluation criteria currently used for routine FISH analysis of tumors.
| Tumor Entity | DNA Probe(s) for | Tissue | Evaluation Criterium | Cut-Off Value | N = Nuclei to Be Scored | References |
|---|---|---|---|---|---|---|
| Lung cancer | ALK | FFPE * | rearrangement | PAN † ≥ 50% | Jurmeister et al. [ | |
| ROS1 | FFPE * | rearrangement | PAN † ≥ 50% | Jurmeister et al. [ | ||
| RET | FFPE * | rearrangement | PAN † ≥ 50% | Tsuta et al. [ | ||
| MET | FFPE * | amplification | MET/CEP7 ǁ- ratio ≥2 | Bubendorf et al. [ | ||
| Different types of lymphomas | Bcl2 | FFPE * | rearrangement | PAN † ≥ 50% | Horn et al. [ | |
| Bcl6 | FFPE * | rearrangement | PAN † ≥ 50% | Horn et al. [ | ||
| Myc | FFPE * | rearrangement | PAN † ≥ 50% | Horn et al. [ | ||
| Breast cancer | ERBB2/CEP17 | FFPE * | amplification/CNG ‡ | ERBB2/CEP17 ǁ Copy Ratio ≥2.0 | ASCO/CAP guidelines 2018 [ | |
| Melanoma | 11q13/ 6q23/6p25/ | FFPE * | loss/ CNG‡ | PAN † ≥ (29–55%)/ multiparameter model/ CR ¶ | Gerami et al. [ | |
| Bladder cancer | Urovysion (chrom. 3,7,9p21,17) | Urine cytology | CNV § | CNG ‡ for chromosomes 3,7,17 (≥4); 9p21 loss in ≥12 | Huysentruyt et al. [ | |
| Liposarcoma | MDM/CEP12 | FFPE * | amplification | MDM2/CEP12 ǁ- ratio ≥2; | Coindre et al., Creytens et al. [ | |
| Different sarcoma types | DDIT3, EWSR1, FOXO1, FUS SS18, MDM2 | FFPE * | rearrangement | PAN † ≥ 50% | Modified from Horn et al. [ | |
| Oligodendroglioma | 1p/19q | FFPE * | Loss/ CNG ‡ | 1p/1q and 19q/19p ratio | Modified from Van den Bent et al. [ |
* FFPE: Formalin Fixed Paraffin Embedded, † PAN: Percentage of Abnormal Nuclei, ‡ CNG: Copy Number Gain, § CNV: Copy Number Variation, ǁ CEPx: centromere probe for chromosome x, ¶ CR Chromosome Ratio.
Clinicopathological characteristics of the patient group.
| Patient Population | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Histopathology | CR | PAN | |||||||
| Low-Grade | High-Grade | Normal | Aberrant | <10% | ≥10% | ||||
| Gender | |||||||||
| Male ( | 39 | 14 | 36 | 17 | 30 | 23 | |||
| Female ( | 26 | 8 | 25 | 9 | 24 | 10 | |||
| Age (mean, (SD)) | 57.7 | 60.7 | 57.6 (11,18) | 61.35 | 57.8 | 59.9 | |||
| Histopathology | |||||||||
| Low-grade dysplasia ( | 48 (73%) | 17 (27%) | 43 (65%) | 22 (35%) | |||||
| High-grade dysplasia | 14 (58%) | 8 (42%) | 8 (33%) | 14 (67%) | |||||
| 5-year disease free survival | |||||||||
* significant p-value.
Figure 1(A–C) Representative images of tissue sections of premalignant laryngeal lesions, analyzed by FISH 1/7 with centromere probes for chromosome instability (CI) detection showing disomy for chromosomes 1 (green) and 7 (red) (no CI) (A), trisomy for chromosome 1, and polysomy for chromosome 7 (CI) resulting in an aberrant CR and PAN ≥ 10% (B) and a lesion with only few aberrant nuclei, resulting in a normal CR but PAN ≥ 10% (C). (D,E) Percentage of CI in premalignant laryngeal lesions (low-grade dysplasia versus high-grade dysplasia) CR-FISH (D) and PAN-FISH (E).
Odds ratios of parameters predicting malignant progression.
| Parameter | OR (95% Confidence Interval) | |
|---|---|---|
|
| ||
| Histopathology | 4.0 (1.4–11.2) | 0.009 * |
| (low-grade vs. high-grade) | ||
| CR-FISH | 3.8 (1.4–10.5) | 0.009 * |
| PAN-FISH 0%) | 5.6 (2.0–15.8) | 0.001 * |
|
| ||
| Histopathology | 3.9 (1.3–11.6) | 0.014 * |
| CR-FISH | 3.7 (1.3–10.8) | 0.014 * |
|
| ||
| Histopathology | 2.9 (1.0–8.8) | 0.058 |
| PAN-FISH | 4.6 (1.6–13.4) | 0.005 * |
* significant p-value. Abbreviations: OR, Odds Ratio; CR, Chromosome Ratio; PAN, Percentage of Aberrant Nuclei.
Figure 2(A) Receiver Operating Characteristic-curve (ROC) for histopathological diagnosis (black line a; AUC = 0.64) and in combination with PAN-FISH ≥ 10% (upper dotted line b), AUC = 0.75, optimal sensitivity 71%, specificity 70%. (B) Receiver Operating Characteristic-curve (ROC) for histopathological diagnosis only (black line a) and in combination with CR-FISH (upper dotted line b), AUC = 0.73, optimal sensitivity 75%, specificity 66%.
Figure 3(A–C) Kaplan–Meier survival analyses for histopathology, CR-FISH, and PAN-FISH. (A) Progression-free survival according to histopathological diagnosis; patients with high-grade dysplasia show a significantly shortened progression-free survival as compared to the patients low grade dysplasia; (p = 0.002). (B) Progression-free survival according to CR-FISH. Patients with an aberrant CR show a significantly shortened progression-free survival (p = 0.003). (C) Progression-free survival according to PAN-FISH. Patients with PAN ≥ 10% show a significantly shortened progression-free survival (p = 0.0001).